James H. Doroshow

Research interests

Publications

• Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

  Nature Genetics · 2021 · https://doi.org/10.1038/s41588-020-00750-6

• TPM, FPKM, or Normalized Counts? A Comparative Study of Quantification Measures for the Analysis of RNA-seq Data from the NCI Patient-Derived Models Repository

  Journal of Translational Medicine · 2021 · https://doi.org/10.1186/s12967-021-02936-w

• Abeloff's Clinical Oncology

  Elsevier eBooks · 2020 · 10.1016/c2015-0-05400-4

• The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity

  Cancer Research · 2017 · 10.1158/0008-5472.can-17-0489

• Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2014.60.4009

• Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition

  Journal of Pharmacology and Experimental Therapeutics · 2014 · 10.1124/jpet.113.210146

• Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses

  JNCI Journal of the National Cancer Institute · 2014 · https://doi.org/10.1093/jnci/dju089

• The Exomes of the NCI-60 Panel: A Genomic Resource for Cancer Biology and Systems Pharmacology

  Cancer Research · 2013 · 10.1158/0008-5472.can-12-3342

• Criteria for the use of omics-based predictors in clinical trials

  Nature · 2013 · https://doi.org/10.1038/nature12564

• Molecular mechanisms underlying chronic inflammation-associated cancers

  Cancer Letters · 2013 · 10.1016/j.canlet.2013.08.014

• Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

  Molecular Cancer Therapeutics · 2013 · https://doi.org/10.1158/1535-7163.mct-13-0803

• Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors

  Cancer Discovery · 2012 · 10.1158/2159-8290.cd-12-0049

• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

  Cancer Research · 2012 · https://doi.org/10.1158/0008-5472.can-12-2753

• CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set

  Cancer Research · 2012 · https://doi.org/10.1158/0008-5472.can-12-1370

• Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents

  Proceedings of the National Academy of Sciences · 2012 · 10.1073/pnas.1205943109

• Analysis of Food and Drug Administration–Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines

  Molecular Cancer Therapeutics · 2010 · 10.1158/1535-7163.mct-10-0106

• Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.19.7681

• Bacteria-Induced Intestinal Cancer in Mice with DisruptedGpx1andGpx2Genes

  Cancer Research · 2004 · 10.1158/0008-5472.can-03-2272

• Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

  Blood · 2001 · https://doi.org/10.1182/blood.v98.12.3212

• Mice with combined disruption of Gpx1 and Gpx2 genes have colitis

  American Journal of Physiology-Gastrointestinal and Liver Physiology · 2001 · 10.1152/ajpgi.2001.281.3.g848

• Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.

  Journal of Clinical Oncology · 1995 · 10.1200/jco.1995.13.6.1303

• Expression, characterization, and tissue distribution of a new cellular selenium-dependent glutathione peroxidase, GSHPx-GI.

  Journal of Biological Chemistry · 1993 · 10.1016/s0021-9258(18)53812-6

• Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.

  Journal of Clinical Oncology · 1990 · https://doi.org/10.1200/jco.1990.8.3.491

• Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

  Journal of Clinical Oncology · 1989 · 10.1200/jco.1989.7.4.486

• Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical.

  Journal of Biological Chemistry · 1986 · 10.1016/s0021-9258(17)35747-2

• Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase.

  Journal of Biological Chemistry · 1986 · 10.1016/s0021-9258(17)35746-0

• Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase.

  PubMed · 1983

• Effect of anthracycline antibiotics on oxygen radical formation in rat heart.

  PubMed · 1983

• Enzymatic Defenses of the Mouse Heart Against Reactive Oxygen Metabolites

  Journal of Clinical Investigation · 1980 · 10.1172/jci109642

Current projects

No projects listed.